This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective To explore the association between serum retinoic acid (RA) level in patients with acute ischemic stroke (AIS) and mortality risk in the 6 months after admission.
Methods From January 2015 through December 2016, patients admitted to 3 stroke centers in China for first-ever AIS were screened. The primary endpoint was all-cause mortality or cardiovascular disease (CVD) mortality in the 6 months after admission. The significance of serum RA level, NIH Stroke Scale score, and established risk factors in predicting mortality were determined. The integrated discrimination improvement (IDI) and net reclassification improvement (NRI) statistics were applied in statistical analysis.
Results Of the 1,530 patients enrolled, 325 died within 6 months of admission, with an all-cause mortality of 21.2% and CVD-related mortality of 13.1%. In multivariable analysis, RA levels were expressed as quartiles with the clinical variables. The results of the second to fourth quartiles (Q2–Q4) were compared with the first quartile (Q1); RA levels showed prognostic significance, with decreased all-cause and CVD mortality of 55% and 63%, respectively. After RA was added to the existing risk factors, all-cause mortality could be better reclassified, in association with only the NRI statistic (p = 0.005); CVD mortality could be better reclassified with significance, in association with both the IDI and NRI statistics (p < 0.01).
Conclusions Low circulating levels of RA were associated with increased risk of all-cause and CVD mortality in a cohort of patients with first-incidence AIS, indicating that RA level could be a predictor independent of established conventional risk factors.
Glossary
- 9cRA=
- 9-cis-retinoic acid;
- AIS=
- acute ischemic stroke;
- AUC=
- area under the curve;
- BMI=
- body mass index;
- CI=
- confidence interval;
- CV=
- coefficient of variation;
- CVD=
- cardiovascular disease;
- FBG=
- fasting blood glucose;
- HCY=
- homocysteine;
- HDL=
- high-density lipoprotein;
- HOMA-IR=
- homeostasis model assessment of insulin resistance;
- HR=
- hazard ratio;
- Hs-CRP=
- high-sensitivity C-reactive protein;
- IDI=
- integrated discrimination improvement;
- IL-6=
- interleukin-6;
- IQR=
- interquartile range;
- LDL=
- low-density lipoprotein;
- mRS=
- modified Rankin Scale;
- NIHSS=
- NIH Stroke Scale;
- NRI=
- net reclassification improvement;
- OR=
- odds ratio;
- RA=
- retinoic acid;
- RAR=
- retinoic acid receptor;
- ROC=
- receiver operating characteristic;
- SVZ=
- subventricular zone;
- TC=
- total cholesterol;
- TG=
- triglyceride
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
↵* These authors contributed equally to this work as co–first authors.
↵‡ These authors contributed equally to this work as co–last authors.
- Received May 25, 2018.
- Accepted in final form December 7, 2018.
- © 2019 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Copeptin and NT-proBNP for prediction of all-cause and cardiovascular death in ischemic stroke
Prospective study of restless legs syndrome and total and cardiovascular mortality among women
Total cerebral blood flow and mortality in old age
Interface of Multiple Sclerosis, Depression, Vascular Disease, and Mortality